# Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

> **NCT07192068** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 105 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Sarcoma
- Head &Amp; Neck Cancer
- Colorectal Carcinoma
- Endometrial

## Interventions

- **DRUG:** Zanidatamab

## Key facts

- **NCT ID:** NCT07192068
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2028-03-13
- **Final completion:** 2030-06-24
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07192068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07192068, "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07192068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*